Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Amphastar P

29A
Current price
46 EUR -0.54 EUR (-1.16%)
Last closed 50.53 USD
ISIN US03209R1032
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange Frankfurt Exchange
Capitalization 2 462 319 104 USD
Yield for 12 month +8.33 %
1Y
3Y
5Y
10Y
15Y
29A
21.11.2021 - 28.11.2021

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Address: 11570 6th Street, Rancho Cucamonga, CA, United States, 91730

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

61.5 USD

P/E ratio

15.9651

Dividend Yield

Current Year

+644 395 000 USD

Last Year

+498 987 000 USD

Current Quarter

+182 394 000 USD

Last Quarter

+171 836 000 USD

Current Year

+343 968 000 USD

Last Year

+248 860 000 USD

Current Quarter

+92 048 000 USD

Last Quarter

+87 290 000 USD

Key Figures 29A

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 284 159 008 USD
Operating Margin TTM 30.27 %
PE Ratio 15.9651
Return On Assets TTM 10.13 %
PEG Ratio 2.77
Return On Equity TTM 25.57 %
Wall Street Target Price 61.5 USD
Revenue TTM 712 891 008 USD
Book Value 14.57 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 25.2 %
Dividend Yield
Gross Profit TTM 248 860 000 USD
Earnings per share 3.15 USD
Diluted Eps TTM 3.15 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 49 %
Profit Margin 23.36 %

Dividend Analytics 29A

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 29A

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 29A

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 15.9651
Forward PE
Enterprise Value Revenue 4.019
Price Sales TTM 3.454
Enterprise Value EBITDA 9.5841
Price Book MRQ 3.4518

Financials 29A

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 29A

For 52 weeks

36.56 USD 65.92 USD
50 Day MA 47.82 USD
Shares Short Prior Month 4 352 216
200 Day MA 45.36 USD
Short Ratio 13.18
Shares Short 4 232 894
Short Percent 13.16 %